Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential

Terry Chrisomalis Investing Group Leader Follow Summary Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential best-in-class efficacy for IBD, with combination data expected in 2027. Despite discontinuing SPY072 monotherapy for RA, SYRE retains upside via upcoming PsA, axSpA, and combination readouts in late 2026–2028. With $1.1B in cash and multiple catalysts ahead, SYRE is positioned for leadership in the large IBD and rheumatology markets. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Azon/iStock via Getty Images The last time I spoke about Spyre Therapeutics ( SYRE ) it was with a Seeking Alpha article entitled " Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms ." With This article was written by Terry Chrisomalis 15.2K Followers Follow Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.